IP Library Granted Patent US 6,977,251
Granted Patent B2
US 6,977,251 · App. 09/225,499 · Granted Dec 20, 2005

5-androstene-3β, 17α diol as an inhibitor of tumor growth

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,977,251
App. No.
09/225,499
Granted
Dec 20, 2005
Kind
B2
Abstract

The instant application provides means of accelerating cell aging and programed cell death in tumor cells by administration of 3β,17α androstenediol (αAED) or its ethers or esters.

Claims (15)

1. A composition of matter comprising a carrier and a tumor inhibiting effective amount of a compound selected from the group consisting of 5-androstene-3β,17α-diol and an ester or ether thereof of the formula:

wherein,

R independently are H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR 2 ,

R 2 independently are H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons or phenyl, wherein any phenyl moiety optionally has up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl optionally is a straight chain, branched chain, or the alkyl optionally is wholly or partially cyclized, wherein the composition is a formulation for oral, parenteral, buccal, sublingual, endotracheal or aerosol administration.

2. The composition of claim 1 wherein the compound is 5-androstene-3β,17α-diol.

3. The composition of claim 1 in the form of a tablet.

4. The composition of claim 1 in the form of a capsule.

5. A composition of matter comprising a cyclodextrin and a tumor inhibiting effective amount of a compound selected from the group consisting of 5-androstene-3β,17α-diol and an ester or ether thereof of the formula:

wherein,

R are selected from H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR 2 ,

R 2 are selected from H, alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons or phenyl, wherein any phenyl moiety optionally has up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl optionally is a straight chain, branched chain, or the alkyl optionally is wholly or partially cyclized, wherein said composition is a formulation for oral, parenteral, buccal, sublingual, endotracheal or aerosol administration.

6. The composition of claim 5 wherein the compound is 5-androstene-3β,17α-diol.

7. The composition of claim 5 in the form of a tablet or a capsule.

8. The composition of claim 5 in the form of a parenteral formulation.

9. The composition of claim 5 , wherein said composition is in a form selected from the group consisting of a spray, a cream, a jelly, a suppository, a douching solution, a liquid and an adhesive patch.

Assignments (1)
CHANGE OF NAME Recorded Nov 2, 2012
From: HARBOR BIOSCIENCES, INC.
To: HARBOR DIVERSIFIED, INC.
Reel/Frame 029227/0929 →